Literature DB >> 11316769

Opioids suppress basal and nicotine-induced catecholamine secretion via a stabilizing effect on actin filaments.

E Dermitzaki1, A Gravanis, M Venihaki, C Stournaras, A N Margioris.   

Abstract

Catecholamine secretion and actin filament disassembly are closely coupled in chromaffin cells. Opioid suppression of catecholamine secretion is fast and transient, both characteristics of actin filament involvement. The aim of the present work was to test the hypothesis that opioids suppress catecholamine secretion via an inhibitory effect on actin filament disassembly. For this purpose we used the PC12 rat pheochromocytoma cell line. Norepinephrine and dopamine were measured by enzyme-linked immunosorbent assay or RIA. Polymerized actin was measured by rhodamine-phalloidin and visualized by confocal laser scanning microscopy. Opioids suppressed basal catecholamine secretion. The onset of this effect was fast and transient, peaking at 2 min, and was reversible by opioid antagonists. Synchronously, opioids suppressed actin filament disassembly; this was also reversible by opioid antagonists. Cytochalasin B prevented the inhibitory effect of opioids on catecholamine secretion. In addition, opioids suppressed the stimulatory effect of nicotine on catecholamine secretion and actin depolymerization. Changes in actin cytoskeleton in neuron-like PC12 cells make them resistant to both effects of opioids, i.e. on catecholamine secretion and actin disassembly. In conclusion, our data suggest that the suppressive effect of opioids on basal and nicotine-induced catecholamine secretion may result from an opioid-provoked stabilization of cortical actin. It also appears that basal catecholamine secretion is associated with opioid-sensitive machinery regulating the continuous formation of short-lived areas of cortical actin filament disassembly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316769     DOI: 10.1210/endo.142.5.8133

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus.

Authors:  Septimiu Vele; Sofiya Milman; Harry Shamoon; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

2.  Opioid receptor blockade prevents exercise-associated autonomic failure in humans.

Authors:  Sofiya Milman; James Leu; Harry Shamoon; Septimiu Vele; Ilan Gabriely
Journal:  Diabetes       Date:  2012-04-20       Impact factor: 9.461

3.  Whole genome expression profiling associates activation of unfolded protein response with impaired production and release of epinephrine after recurrent hypoglycemia.

Authors:  Juhye Lena Kim; Edmund F La Gamma; Todd Estabrook; Necla Kudrick; Bistra B Nankova
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

4.  Corticotrophin-Releasing Factor (CRF) and the urocortins are potent regulators of the inflammatory phenotype of human and mouse white adipocytes and the differentiation of mouse 3T3L1 pre-adipocytes.

Authors:  Eirini Dermitzaki; George Liapakis; Ariadne Androulidaki; Maria Venihaki; John Melissas; Christos Tsatsanis; Andrew N Margioris
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.